Drugs of Abuse Confirmation/Quantitation - Benzodiazepines - Meconium
Ordering Recommendation

• Use for infant drug testing when only benzodiazepine exposure is of clinical interest or when quantity of meconium available for testing is very small (eg, <1 g).
• Preferred test is Drugs of Abuse Panel, Meconium - Screen with Reflex to Confirmation/Quantitation (0092516).

Quantitative Liquid Chromatography-Tandem Mass Spectrometry
1-4 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
All meconium (blackish material) excreted until milk/formula based stool (yellow-green) appears. 
Specimen Preparation
Transport 1 g (equivalent to 1/2 inch cube) for each separate confirmation required. (Min: 0.5 g or 1/4 inch cube) 
Storage/Transport Temperature
Room temperature. 
Unacceptable Conditions
Ambient: 1 week; Refrigerated: 3 months; Frozen: 1 year 
Reference Interval
By report
Interpretive Data
Methodology: Quantitative Liquid Chromatography-Tandem Mass Spectrometry

Drugs covered:
alprazolam, alpha-hydroxyalprazolam, clonazepam, 7-aminoclonazepam, diazepam, chlordiazepoxide, lorazepam, midazolam, alpha-hydroxymidazolam, nordiazepam, oxazepam, and temazepam.

Positive cutoff:
20 ng/g unless specified below:
Alprazolam 5 ng/g
Alpha-hydroxyalprazolam 5 ng/g
Diazepam 5 ng/g
Clonazepam 5 ng/g
7-aminoclonazepam 5 ng/g

Meconium begins to form between the 12th and 16th week of gestation. Meconium drug testing can detect maternal drug use during the last 4 to 5 months of pregnancy. A negative result does not exclude the possibility that a mother used drugs during pregnancy. Detection of drug use depends on the quantity and quality of the specimen tested as well as the pattern and frequency of drug(s) used by mother. The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

For medical purposes only; not valid for forensic use.

Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Hotline History
View Hotline History
CPT Code(s)
Component Test Code*Component Chart NameLOINC
0092520Drug Confirmation, Benzodiazepine, Mec29160-9
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
  • 7-Aminoclonazepam
  • Alpha-Hydroxyalprazolam
  • Alpha-Hydroxytriazolam
  • Alprax
  • Alprazolam
  • Ansilan
  • Apo-Triazo
  • Ativan
  • Centrax
  • Chlorazepate
  • Chlordiazepoxide
  • Clonazepam
  • Clonopin
  • Dalmadorm
  • Dalmane
  • Demetrin
  • Desalkylflurazepam
  • Desmethyldiazepam
  • Desoxydemoxepam
  • Diastat
  • Diazepam
  • Dormicum
  • Halcion
  • Hydroxyethylflurazepam
  • Hypnovel
  • Klonopin
  • Librium
  • Lorazepam
  • Lysanxia
  • Medazepam
  • Midazolam
  • Mono Demetrin
  • Niravam
  • Nobrium
  • Nordazepam
  • Nordiazepam
  • Novo-Clopate
  • Oxazepam
  • Paxipam
  • Pozapam
  • Prasepine
  • Prazene
  • Prazepam
  • Ravotril
  • Reapam
  • Restoril
  • Rudotel
  • Serax
  • Temazepam
  • Temesta
  • Tranxene
  • Trepidan
  • Valium
  • Valrelease
  • Versed
  • Xanax
  • Xanor